Mark Vaeck - CEO, Complix
Short description of the presentation:
Complix is a biopharmaceutical company developing Alphabodies, a unique class of transformative protein therapeutics. Alphabodies represent a disruptive technology platform that has the potential to address "undruggable" intracellular disease targets by combining efficient cell penetration capacity with selective and high-affinity (antibody-like) binding to such intracellular protein targets.
Therapeutic focus is on oncology and the lead product is an antagonist of MCL-1, an intracellular cancer target involved in apoptosis regulation. End of last year Complix signed a 280M$ collaboration deal with Merck Inc, for the discovery and development of Alphabodies against two non-disclosed intracellular oncology targets.
Biography of the speaker:
Mark Vaeck has more than 25 years of experience in the biotech and pharma industry and has raised over €80 million in equity financing. In 2008 he co-founded the biopharmaceutical company Complix (Belgium) and was appointed as its CEO in May 2010.
Before that, from 2006 until 2010 he was the founding CEO of ActoGeniX (Belgium). From 2001 until 2006 he was the CEO of Ablynx (Belgium), which he co-founded in June 2001. Prior to joining Ablynx, Mark was Chief Operating Officer of Ceres Inc (US), a NASDAQ listed company that develops innovative technologies for biofuel production. From 1993 until 1998 he served as Director Business Development and thereafter as CEO of Keygene (The Netherlands). Between 1983 and 1993 he held several management positions in the biotech and pharma industry, including Director Business Development at EuroCetus (Chiron Corp.), Manager Licensing at UCB Pharma, and Manager Business Development at Plant Genetic Systems.
Mark holds a PhD in Immunology from the University of Brussels (1982).